Ultragenyx Pharmaceutical Inc RARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RARE is a good fit for your portfolio.
News
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
-
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
-
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx to Participate at Investor Conferences in March
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Trading Information
- Previous Close Price
- $45.11
- Day Range
- $43.61–45.55
- 52-Week Range
- $31.52–54.98
- Bid/Ask
- $41.82 / $45.99
- Market Cap
- $3.65 Bil
- Volume/Avg
- 670,632 / 711,335
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,276
- Website
- https://www.ultragenyx.com
Comparables
Valuation
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 28.06 | — |
Price/Book Value | 13.48 | 6.19 | 12.77 |
Price/Sales | 7.64 | 7.50 | 8.70 |
Price/Cash Flow | — | 39.12 | — |
Price/Earnings
RARE
NBIX
SRPT
Financial Strength
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Quick Ratio | 2.32 | 2.25 | 3.23 |
Current Ratio | 2.61 | 2.45 | 3.95 |
Interest Coverage | −8.62 | 73.20 | −26.54 |
Quick Ratio
RARE
NBIX
SRPT
Profitability
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Return on Assets (Normalized) | −33.88% | 14.51% | −1.58% |
Return on Equity (Normalized) | −233.97% | 20.57% | −7.14% |
Return on Invested Capital (Normalized) | −182.73% | 17.92% | −4.76% |
Return on Assets
RARE
NBIX
SRPT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yvxwfydnm | Fxzyj | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tpkgfpxwc | Sbxmyfp | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlmhtyv | Qmgmxkz | $99.6 Bil | |
MRNA
| Moderna Inc | Rtjbbqm | Frz | $38.8 Bil | |
ARGX
| argenx SE ADR | Cmrndpwrl | Xmw | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Hhhmfbyyg | Hdwc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Knqlvzdn | Qvsbfjv | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ppyjkddw | Vrfqv | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fbckbnkm | Nnxczf | $12.4 Bil | |
INCY
| Incyte Corp | Hfdrchw | Ndtqpw | $11.9 Bil |